Antibody data
- Antibody Data
- Antigen structure
- References [1]
- Comments [0]
- Validations
- Western blot [1]
- Immunohistochemistry [1]
- Other assay [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PA5-40841 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- EGR3 Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Synthetic peptide
- Reactivity
- Human
- Host
- Rabbit
- Isotype
- IgG
- Vial size
- 100 µL
- Concentration
- 0.5 mg/mL
- Storage
- -20° C, Avoid Freeze/Thaw Cycles
Submitted references Expression and prognostic value of the transcription factors EGR1 and EGR3 in gliomas.
Knudsen AM, Eilertsen I, Kielland S, Pedersen MW, Sørensen MD, Dahlrot RH, Boldt HB, Munthe S, Poulsen FR, Kristensen BW
Scientific reports 2020 Jun 9;10(1):9285
Scientific reports 2020 Jun 9;10(1):9285
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of human stomach cells using an anti-EGR3 polyclonal antibody (Product # PA5-40841).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemistry analysis of placenta tissue using an anti-EGR3 polyclonal antibody (Product # PA5-40841).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 2 Expression of EGR1 and EGR3 in infiltrating tumour cells. (A-C) Representative HE, P53, and double-fluorescence images with P53/EGR1 on tissue sections from one of the tumours included in the cohort. 1 = central tumour area. 2 = intermediate tumour area. 3 = peripheral tumour area. Scale bar = 2.5 mm. DAPI-stained nuclei = blue, P53-positive nuclei = green, EGR1/3-positive nuclei = red, double-positive nuclei, i.e. positive for both P53 and EGR1/3 = orange. ( D,E) The EGR1 fraction and staining intensity in EGR1 + tumour cells was significantly reduced from central tumour to periphery. ( F) Ivy GAP data showed a trending but non-significant decline in EGR1 mRNA levels between central tumour and tumour periphery. ( G,H) The EGR3 fraction remained constant across the different tumour regions, while the mean staining intensity increased significantly in peripheral tumour cells compared to central tumour cells. I) Ivy Gap EGR3 mRNA data also showed an increase in EGR3 intensity in the intermediate and peripheral areas compared to central tumour. * = P < 0.05. ** = P < 0.01. *** = P < 0.001.